Neisseria Meningitidis Completed Phase 3 Trials for Bordetella pertussis pertactin antigen (formaldehyde inactivated) (DB10992)

DBCOND0030896 (Neisseria Meningitidis)Completed3 IdentifierTitlePurposeDrugs
NCT00289783Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate VaccinePrevention
NCT00586612Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm InfantsPrevention
NCT01978093Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of AgePrevention
NCT00322335Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenCPrevention
NCT00327184Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC VaccinePrevention
NCT00345579Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of AgePrevention
NCT01218451NeisVac-C Single Prime Study in InfantsPrevention